Skip to main content

Table 2 Subgroup analyses for MACE

From: Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

Subgroups

HR (95% CI)

P value

P value for interaction

Age

  < 60–65 years

0.92 (0.77, 1.10)

0.38

0.58

  ≥ 60–65 years

0.85 (0.79, 0.93)

0.001

 

Gender

 Male

0.91 (0.85, 0.98)

0.02

0.53

 Female

0.87 (0.78, 0.98)

0.02

 

Race

 White

0.94 (0.88, 1.01)

0.09

0.12

 Black

0.77 (0.59, 1.00)

0.05

 

 Asian

0.78 (0.62, 0.97)

0.03

 

Body mass index

  < 30 kg/m2

0.93 (0.83, 1.05)

0.22

0.69

  ≥ 30 kg/m2

0.88 (0.81, 0.96)

0.008

 

Glycated hemoglobin level

  < 8.0–8.5%

0.91 (0.83, 1.00)

0.04

0.73

  ≥ 8.0–8.5%

0.89 (0.82, 0.97)

0.01

 

Insulin therapy

 Yes

0.88 (0.81, 0.97)

0.01

0.98

 No

0.88 (0.80, 0.98)

0.01

 

Duration of diabetes

  < 10–15 years

0.91 (0.81, 1.02)

0.09

0.74

  ≥ 10–15 years

0.89 (0.82, 0.96)

< 0.01

 

History of congestive heart failure

 Yes

0.96 (0.85, 1.08)

0.47

0.27

 No

0.87 (0.77, 1.00)

0.05

 

Estimated GFR

  ≥ 60 mL/min/1.73m2

0.91 (0.79, 1.05)

0.19

0.82

  < 60 mL/min/1.73m2

0.89 (0.72, 1.09)

0.25

 

  ≥ 30 mL/min/1.73m2

0.88 (0.82, 0.95)

< 0.001

0.81

  < 30 mL/min/1.73m2

0.87 (0.55, 1.39)

0.57

 
  1. CI confidence interval, GFR glomerular filtration rate, HR hazard ratio, MACE major adverse cardiovascular event